552335-47-4

Basic information

• Product Name: L-Proline, 1-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-1-oxo-8-nonen-1-yl]-4-hydroxy-, (4R)-
• Synonyms: L-Proline, 1-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-1-oxo-8-nonen-1-yl]-4-hydroxy-, (4R)-;(4R)-1-[(2S)-2-[[(1,1-Dimethylethoxy)carbonyl]amino]-1-oxo-8-nonenyl]-4-hydroxy-L-proline;(2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxylic acid
• CAS NO: 552335-47-4
• Molecular Formula: C₁₉H₃₂N₂O₆
• Molecular Weight: 384.46718
• Mol File: 552335-47-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-Proline, 1-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-1-oxo-8-nonen-1-yl]-4-hydroxy-, (4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 1-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-1-oxo-8-nonen-1-yl]-4-hydroxy-, (4R)-(552335-47-4)
• EPA Substance Registry System: L-Proline, 1-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-1-oxo-8-nonen-1-yl]-4-hydroxy-, (4R)-(552335-47-4)

Safety Data

• Hazardous Substances Data: 552335-47-4(Hazardous Substances Data)

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 790305-05-4 tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-hydroxy-5,16-dioxo-1,2,3,5,6,7,8, 9,10,11,13a,14,14a,15,16,16a-hexadecahydronaphthylcyclopropanoyl[e]pyrrolo[1,2-a][1,4]diazacyclopenta decyne-6-yl-carbamate 
• 1029259-59-3 C₃₈H₄₈N₄O₈S 
• 1029259-57-1 C₃₂H₄₄N₄O₈S 
• 552335-44-1 (1R,2S)-ethyl 1-((2S,4R)-1-((S)-2-(((tert-butoxy)carbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate 

Relevant articles and documents

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.